Skip to main content
. 2014 Dec 19;6(3):1769–1778. doi: 10.18632/oncotarget.2754

Figure 2. Cell viability and combination index of HeLa and HepG2 treated with drug combination.

Figure 2

Panel A: Growth inhibition in HeLa and HepG2 cells after incubation for 24 h with a combination of HPRP-A1/HPRP-A2 (16 μg/ml) and DOX/EPI (1.2 μg/ml). Results are expressed as percentage of the control ± SD of three independent experiments. Panel B: combination index (Q) of the combination treatment of HPRP-A1/HPRP-A2 and DOX/EPI, where Q < 0.85, Q > 1.15 and 0.85 < Q < 1.15 indicate antagonism, synergy, and additive effect, respectively.